Physician profile
John L Dolan
NPI 1467416800
$370,482.15
in general payments reported to CMS, 2019-2025
31 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160K · 2020: $72K · 2021: $69K · 2022: $60K · 2023: $6,951 · 2024: $1,430 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,098 · Food and Beverage: $3,262 · Travel and Lodging: $135 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,097.50 |
| Food and Beverage | $3,261.72 |
| Travel and Lodging | $134.93 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $162,653.87 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Abbvie INC. | $35,625.35 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Genzyme Corporation | $34,796.73 | 2019-2021 | |
| Amgen INC. | $32,416.60 | 2019-2025 | Uplizna |
| Acorda Therapeutics, INC | $29,317.71 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $19,804.96 | 2019-2024 | Ingrezza |
| Allergan, INC. | $19,601.21 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $11,584.27 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $10,355.10 | 2022 | |
| Mallinckrodt Enterprises LLC | $6,969.70 | 2019 | |
| Alexion Pharmaceuticals, INC. | $5,413.62 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $352.47 | 2024-2025 | |
| Eisai INC. | $276.07 | 2023-2025 | |
| Lundbeck LLC | $255.32 | 2023-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $169.64 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $154.39 | 2024-2025 | Crexont, Ongentys |
| Biogen, INC. | $150.00 | 2019 | |
| Pfizer INC. | $103.84 | 2024-2025 | |
| Ucb, INC. | $83.67 | 2023-2025 | Zilbrysq, Rystiggo |
| Novartis Pharmaceuticals Corporation | $63.12 | 2019-2025 | |
| Neurelis, INC. | $61.28 | 2025 | Valtoco |
| Lilly USA, LLC | $50.63 | 2019-2025 | Kisunla |
| Genentech USA, INC. | $44.55 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Catalyst Pharmaceuticals, INC. | $35.61 | 2024 | |
| Emd Serono, INC. | $33.16 | 2019-2022 | |
| Argenx US, INC. | $23.12 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Merz Pharmaceuticals, LLC | $20.25 | 2025 | Inbrija, Xeomin, Ampyra |
| Cycle Pharmaceuticals INC | $17.93 | 2025 | Tascenso Odt, Bafiertam |
| Sk Life Science, INC. | $17.34 | 2025 | |
| Tg Therapeutics, INC. | $16.94 | 2025 | |
| Sanofi-Aventis U.S. LLC | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.